Article Text
Statistics from Altmetric.com
Background
Bortezomib belongs to the family of proteasome inhibitors and is a well established first line drug in multiple myeloma (MM).1 In mouse models of lupus nephritis, bortezomib ameliorated glomerulonephritis, prolonged survival and reduced autoantibody production.2
Case report
We report the case of a 63-year-old woman who presented with systemic lupus erythematosus (SLE) fulfilling the American College of Rheumatology (ACR) criteria and requiring treatment for autoimmune thrombocytopoenia, Coombs positive autoimmune haemolytic anaemia, polyarthritis and hair loss. Anti-nuclear antibody (ANA), extractable nuclear antigen (ENA) (U1 riboucleoprotein (U1RNP)) and anti-double-stranded (ds)DNA antibody tests were positive, and serum complement C3 and C4 levels were decreased (European Consensus …
Footnotes
-
Competing interests None.